Please login to the form below

Not currently logged in
Email:
Password:

Former Amgen EVP Roger Perlmutter joins Heptares board

Also has experience at Merck & Co

Roger Perlmutter, HeptaresHeptares has appointed Amgen's former executive VP, R&D, Dr Roger Perlmutter, to its board of directors.

UK-based Heptares, which focuses on researching medicines that target G protein-coupled receptors across a range of conditions, has made several deals recently with large pharma companies, including AstraZeneca and Shire, and is looking to Dr Perlmutter to help ensure their success.

“We are delighted to welcome Roger to our Board and look forward to benefiting from his extensive US, big biotech and big pharma experience as Heptares advances its pipeline into clinical development,” said John Berriman, Heptares' chair.

Dr Perlmutter served in his executive VP position at Amgen from 2001 to 2012 following a spell at Merck & Co where he was executive VP of worldwide basic research and preclinical development.

Prior to joining Merck in 1997, he was professor and sounding chair of the department of immunology at the University of Washington in Seattle, US.

Dr Perlmutter said: “Heptares has pioneered structure determination in GPCRs, and has used this information to develop leading therapeutic candidates in metabolic and neuropsychiatric disease.

“I am eager to help Malcolm Weir and his team translate these impressive assets into novel therapeutics that will make a difference for patients around the world.”

23rd October 2012

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Junior Doctor contracts – PR winners and losers
GCI Health's Caroline Howley on who's winning the PR battle around the junior doctors' strike....
21_Faster_results.png
How to get faster results with digital communication
Everyone is under pressure to deliver results fast, so how can you speed up the positive effects of your e-detailing and multichannel communication? One proven answer is to get the...
Business as usual
MHRA explains that its emphasis will remain firmly on vetting when it comes to pharma advertising...

Infographics